FDA approves Capvaxive pneumococcal 21-valent conjugate vaccine

June 24 2024, by Lori Solomon

The U.S. Food and Drug Administration has approved Merck's Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.


The priority review was based on the pivotal Phase III STRIDE-3 trial, which compared Capvaxive to pneumococcal 20-valent conjugate vaccine in adults ages 18 years and older, who had not previously received a pneumococcal vaccine, as well as the Phase III STRIDE-5 and STRIDE-6 trials, which evaluated Capvaxive in vaccine-naive and vaccine-experienced adults.

Capvaxive includes eight unique serotypes not covered by other currently approved pneumococcal vaccines, but that are responsible for approximately 27 percent of invasive pneumococcal disease cases in adults ages 50 years and older and approximately 30 percent of cases in adults ages 65 years and older, according to epidemiological data.
The company says the vaccine covers serotypes responsible for approximately 84 percent of invasive pneumococcal disease in adults ages 50 years and older.

"Today's approval is a testament to our population-specific strategy behind Capvaxive, which demonstrated robust immunogenicity in a range of adult populations and is driven by a deep understanding of pneumococcal disease," Dean Y. Li, M.D., Ph.D., from Merck Research Laboratories, said in a statement.

"We are proud to provide Capvaxive as a new option specifically designed to help protect against the majority of invasive pneumococcal disease-causing serotypes in adults."

More information: More Information

Copyright © 2024 HealthDay. All rights reserved.


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.